SPAC
Talawar Tx SPAC Merger: A Preclinical Biotech Cash-Runway Test
Talawar Tx is a preclinical biotechnology company focused on bispecific antibodies for immunology and inflammatory diseases, and it is going public through a merger with JATT II Acquisition Corp. The deal is expected to close in the second half of 2026, with the setup favoring investors who want exposure to a large-market biotech story but should watch redemption risk and dilution closely.
Jul 5, 20266 MIN